IN8bio Inc. (INAB)
NASDAQ: INAB
· Real-Time Price · USD
2.10
-0.03 (-1.41%)
At close: Oct 16, 2025, 3:59 PM
2.06
-1.67%
After-hours: Oct 16, 2025, 06:08 PM EDT
-1.41% (1D)
| Bid | 2.02 |
| Market Cap | 9.51M |
| Revenue (ttm) | 2.53M |
| Net Income (ttm) | -23.89M |
| EPS (ttm) | -9.16 |
| PE Ratio (ttm) | -0.23 |
| Forward PE | -0.82 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 2.39 |
| Volume | 66,761 |
| Avg. Volume (20D) | 81,887 |
| Open | 2.15 |
| Previous Close | 2.13 |
| Day's Range | 2.04 - 2.17 |
| 52-Week Range | 1.91 - 16.71 |
| Beta | 0.03 |
| Ex-Dividend Date | n/a |
About INAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol INAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for INAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
-0.81%
IN8bio shares are trading lower after the company ...
Unlock content with
Pro Subscription
5 months ago
-9.55%
IN8bio shares are trading lower. The company announced new preclinical data from its INB-619 program at the 2025 American Society of Gene & Cell Therapy Annual Meeting
2 years ago · proactiveinvestors.com
IN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatmentIN8bio (NASDAQ:INAB), Inc shares slid 16% to $2.51 in early Tuesday trading after the biopharmaceutical company announced that it has received orphan drug designation from the US Food and Drug Adminis...
